Roche Holding AG (ROGZ.XC)
- Zacks
Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod
Roche (RHHBY) obtains approval for the subcutaneous formulation of relapsing multiple sclerosis drug Ocrevus in Europe. In addition, a review of the company's MAA for gene therapy, Elevidys, is also underway.
- GlobeNewswire
Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis
OCREVUS subcutaneous (SC) injection offers a new, 10-minute administration of OCREVUS with comparable efficacy and safety to intravenous infusion (IV) OCREVUS SC provides an additional treatment option without the need for IV facilities, expanding accessibility for patientsRoche is working closely with national health systems in Europe to ensure people with multiple sclerosis can access OCREVUS SC as quickly as possible Basel, 25 June 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today tha
- Globe Newswire
Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories
The cobas® c 703 and cobas® ISE neo analytical units, deliver higher testing capacity and increased automation helping to improve laboratory workflows and advance patient care.The new cobas c 703 analytical unit offers industry-leading high throughput clinical chemistry testing1 with up to 2,000 tests per hour and 70 reagent positions, doubling the existing clinical chemistry throughput on cobas pro integrated solutions.The new cobas ISE neo analytical unit delivers more efficient ISE testing, r
